A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To investigate the objective response rate in patients with ROS1 or ALK over-expressed
locally advanced, or metastatic intrahepatic or hilar cholangiocarcinoma receiving LDK378
Secondary objectives:The progression-free survival ,The disease control rate ,The overall
survival ,The toxicity profiles , The correlation between clinical outcomes and the potential
predictive biomarker for tumor response
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
National Cheng-Kung University Hospital National Taiwan University Hospital